A cough medication is poured in this picture illustration taken October 19, 2022. REUTERS/Ajeng Dinar Ulfiana/Illustration
Companies Riemann A/s Follow
NEW DELHI, Aug 2 (Reuters) – India has found violations related to manufacturing and laboratory practices at drugmaker Riemann Labs, whose cough syrup was linked to the deaths of children in Cameroon, a government health official told Reuters on Wednesday.
Authorities have stepped up scrutiny of drugmakers after some cough syrups made in India were linked to deaths of dozens of children overseas.
Riemann Labs did not respond to requests for comment from Reuters. It is the fourth Indian cough syrup maker to stop production after regulators found lapses.
Rajesh Bhatia, one of the three directors at Riemann Labs, had told Reuters previously he was not aware of the matter.
Regulators inspected the company’s production unit in Madhya Pradesh state and issued a notice after finding lapses, said Sudam Khade, the state’s drugs controller.
India finds ‘violations’ at cough syrup maker linked to Cameroon deaths
